Product
JS108
1 clinical trial
1 indication
Indication
CancerClinical trial
A Phase I, Open-label, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of Recombinant Humanized Anti-Trop2 mAb-Tub196 Conjugate in Patients With Advanced Solid Tumors.Status: Terminated, Estimated PCD: 2023-06-14